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1 Abstract 

2 

3 Although there is increasing evidence that individuals already infected with 

4 HIV-l can be infected with a heterologous strain of the virus, the extent of protection 
5 against superinfection conferred by the first infection and the biologic consequences of 
6 superinfection are not well understood. We explored these questions in the siIlJ,ii;ln 
7 immunodeficiency virus (SIV)/rhesus monkey model of HIV-I/AIDS......U1""'-·f1 
8 cohorts of rhesus monkeys with either SIVmac251 or SIVsj nE6 
CJ 
9 animals to the reciprocal virus through intrarectalil16culab ons. Emrllovine: <ldJuanfitative ~ 
2' 
a. 
a 
~10 real-time polymerase chain reaction (q 
3 
11 kinetics of the two strains of virus for"l O weea. \Ve·fl)\lnd that primary infection with a s: i» 
(f) 
3 
o12 replication-competent i irys didn ot protea~ ~gai1iS~acquisition of infection by a 	 to 
~ 
() 
~ 
relative susceptibility to superinfection was not correlated with 	 0' r 
iil 
-< 
o 
:J16 eD4+""T 'Count, CD4+ memory T cell subsets, cytokine production by virus-specific 
'­~ 
:J 
6i17 (;08+ or CD4+ cells, or neutralizing antibodies at the time of exposure to the second 	
-< 
_w 
~18 virus. Although there were transient increases in viral load of the primary virus and a 	 o 
<0 
19 modest decline in CD4 + T cell counts after superinfection, there was no evidence of 
20 disease acceleration. These findings indicate that an immunodeficiency virus infection 
21 confers partial protection against a second immunodeficiency virus infection, but this 
22 protection may be mediated by mechanisms other than classical adaptive immune 
23 responses. 
13 lativt?Control of the superinfecting virus. In animals 
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2 Introduction 

3 

4 Superinfection with human immunodeficiency virus (HIV) is the infection of an 

HIV seropositive individual with a second heterologous strain of the virus after infection 
6 
7 and intersubtype superinfection in settings of intravenous drug use, structu 
8 interruptions, and with strains that are resistant to antiretroviral 
9 32, 39, 42, 43, 52, 60, 66) . Epidemiologic studies have sU'!!treStad filat the freciuenev.D-f o 
o 
~ 
superinfection ranges from rare to as high a~ 5 'i?wyea'riq high-ri\kjl~opulations (9, 10, o ~ 
2i 
11 15,20,24, 27, 31,40,41,51,59, ~, . - e mains unclear how readily a 3 
~: 
~ 12 superinfections occur afteF. inlljYidual to a heterologous strain of 3 
o 
cO 
13 virus. Furthermore, th ~ ~ 
Z 
14 superinfepti~n, such as thxtiJni.ng.gYexposure to a second virus or the immunologic r Jl 
ffi 
(1) 
II> 
Pose9'mjlividual, have not been well-defined. It is also uncertain whether o :::T 
r 
fr 
iil16 mp.sa.iDf~n iSTnvariably associated with the loss of HIV containment and clinical -< 
o 
::l 
c... 
II> 
::l 
II> 
17 deterioration (8, 17, 21, 23, 26, 27, 30, 60). Understanding the risks for and the C 
-< 
_w18 biological consequences of HIV superinfection will not only clarify an important clinical 
I\:l 
o 
o 
CD 
19 problem, it may also provide important insights into the nature of the immune responses 
that may confer protection against the initial acquisition of HIV. 
21 The nonhuman primate model provides an ideal means of studying the 
22 pathogenesis of HIV-1 superinfection. This system allows for control of many important 
23 variables, including the dose, strain, route, and timing of infection. However, there have 
24 only been a few animal studies that have attempted to explore the biology of 
superinfection. The implications of these studies are uncertain because they have been 
3 

done in models in which infected monkeys do not develop AIDS and the viruses used are 
2 either replication-incompetent or replicate at low levels (11-13, 18,36-38,46-48,53,56­
3 58,61-64). Therefore, it is unclear whether we can extrapolate from these studies the 
4 frequency HIV -1 superinfection, the implications of superinfection on HIV pathogenesis, 
5 and the feasibility of inducing broadly cross-protective immune responses. 
6 In the present study, we have developed a rhesus monkey m~dero: 
7 superinfection to examine whether infection with replicatiC1n..comJietent Sl.V-eonfers a 
o 
8 relative resistance to superinfection and elucidate~tbEfactOrs that influence the clinical ~ 
~ 
a 
~9 course of infection with a second virus.AVe);how ·that..altb.6ugh prioN nfection with SlY 
3 
10 does not protect against subseguen~ufq.scrQJftllleIlge~ith a heterologous SIV isolate, 	 ~: ~ 
3 
11 the primary infection q6e.("atterltiate th''dpl~~apacity of the second virus. 	 cO o 
~ 
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1 Materials and Methods 

2 

3 Animals. Fourteen adult rhesus monkeys (Macaca mulatta) were used in this study. All 

4 animals were housed at Bioqual (Rockville, MD) and maintained in accordance with the 
5 Association for Assessment and Accreditation of Laboratory Animal Care guidelines at 
6 National Institutes of Health. 
7 
8 SIV challenge stocks. The viruses used in this study includ 
o 
9 pathogenic SIVmac251 and pathogenic SIVsmE6 
'0 
~ 
10 NIAIDfNIH). The stock of SIVmac25 l...ftsrexOahiled..On J{uman PBM~ and the stock of ~ 
a 
3 
11 SIVsmE660 was expanded on rhes~-'o~;.pBM(;. "'fo initiate intravenous infections, '$: i» 
'" 3 
o12 2.1x105 RNA copies of~ma~251 a~.{V~O were used. 6.3x107 RNA copies of 	
.a 
~ 
~ 13 108 cbpies ofJSI"Vsm'E660 were used for the intrarectal exposures. 	 Z 
r 
lJ 
(D 
(Dere nreviOusly shown to reproducibly initiate mucosal infections '" SIJ g. 
r 
5' 
iil 
-< 
o 
:J 
c.... 
SIJ 
:J 
C 
SIJ17 QOantitative real-time peR. Plasma SIV mac251 and SIV smE660 RNA levels were 	
-< 
.w 
~18 determined using a two-step quantitative RT -PCR assay. Four sets of strain-specific 	 o 
CD 
19 probes and primers for gag and env were used to distinguish and quantify S IV mac251 
20 and SIVsmE660. Viral RNA was extracted and purified from plasma using the QIAmp 
21 Viral RNA mini kit (Qiagen, Valencia, CA). RNA were subjected to reverse 
22 transcription (RT) with MultiScribe Reverse Transcriptase (Applied Biosystems, Foster 
23 City, CA) to generate cDNA products for quantitative PCR using the env RT primer 5'­
24 GAACCCTAGCACAAAGACCCC-3' and the gag RT primer of 5'­
14 
15 '). 
16 
5 

(Applied Biosystems, Foster City, CA). cDNA were amplified with SIVsmE660 TaqlVJill~ 
env and gag probes that were labeled with 6-carboxyfluorescein (FAM) and 
dyeBHQTMl, while the SIVmac251 env and gag TaqMan probes 
Quasar 670 and quencher dye BHQTM2 (Biosearch Techn.9k1ii~ 
each sample, analyses for SIVmac251 and SIVM~~c; 
both env and gag. 
were as follows : 
mac'261 811 
smE660 gag 
smE660 env 
!ilev"9i 
Probe 
Forward 
Reverse 
Probe 
Forward 
Reverse 
Probe 
Forward 
Reverse 
Probe 
1 GGTGCAGCAAATCCTCT-3'. These primers were designed to anneal to conserved 
2 regions of gag and env that are shared by the two viral strains. 
3 The subsequent qPCR reactions were set up using TaqmanGold Mastermix 
4 
5 
6 
7 
8 
9 
10 
11 
5' -CCAAGAGAGGGAGACCTCA-3' 
5'-CCAAGCCAATCGGAGTGAT-3 ' 
5' -(Ouasar)ACTCCACAGTGACCAGTCTCATAGCA-3' 
5' -TCAATGCTTCTGCCA TTAATCTAG-3' 
JI"T'~~'T'''''''''~'''''''''T''''''''''T' A TTCCCTGACA-3' 
5' -CCTGTTCCAAGCCTGCAC-3' 
5' - ACGCAGGGACAACAACA-3 ' 12 
13 
14 The assembled reactions were run on a Stratagene Mx4000 Multiplex 
15 Quantitative PCR System (Stratagene, La Jolla, CA). Thermal cycling conditions 
16 consisted of 10 min at 95°C for AmpliTaq activation, followed by 45 cycles of 30 sec at 
17 95°C, 35 sec at gene- and strain-specific annealing temperatures as above, and 30 sec at 
18 70°C. Triplicate test reactions were performed for each sample. The nominal copy 
o 
~ 
6" 
~ 
a 
~ 
3 
$ : 
~ 
3 
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~ 
);; 
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numbers for test samples were determined by interpolation onto standard curves of RNA 
standards (duplicate reactions for log 10 dilutions of 101 to 106 copies Eq/ml). All data 
analysis was performed with the Mx4000 v3.00 software (Stratagene, La Jolla, CA). The 
threshold sensitivity of this assay is 100 copies Eq/ml of plasma. Because a low level of 
cross-reactivity of probes between the two strains for SIV could not be elirnina!~d, 
baseline signal for the heterologous strain was substracted for all testeq,_ ples. 
o 
o 
Infection. For intrarectal exposure to SIV, anim 	 ~ 
2" 
0. 
0.anesthesia (Ketamine 10mg/kg intraml!.ScUIp [i. azine 0.5m-gJkg i.m.) with the (l) g 
3 
pelvis propped up at approximatel . cated infant feeding catheter was 	 "$: ill 
'" 3 
inserted gently into th roximately 4-6 inches without causing cO o 
~ 
s;:
any InJury' "diluent (Rb9sph3.te-buffered saline [PBS] wI 0.5% human 	 Z 
r 
JJ 
(l) 
(l)ntlyflushed through the catheter and then 1 ml of the virus was 	 '" Ql 
o 
:J" 
:e£atheter, followed by a 5 ml flush with diluent. The animal was 	 r cr 
iil 
-< 
o 
::J
·s cage and kept tilted at a 45 degree angle until it fully recovered from 	 L\---..- Ql 
::J 
C 
Ql
anesthesia. Six weekly, intra-rectal challenges were carried out with the heterologous 	
-< 
.w 
i?5VIruS. 	 o 
<0 
Antibodies. The antibodies used for surface staining of memory-associated molecules 
and in the intracellular cytokine staining were purchased from BD Biosciences (BD) and 
Beckman Coulter (BC). All reagents were validated and titered using rhesus monkey 
peripheral blood mononuclear cells (PBMCs). The antibodies used in memory staining 
were anti-CD3-PerCP-Cy5.5 (SP34.2 from BD), anti-CD4-fluorescein isothiocyanate 
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multiplyi 
(19Thy5D7 from BC), anti-CD95-allophycyanin (DX2 from BD), and anti-CD28­
phycoerythrin (CD28.2 from BC). For intracellular cytokine staining, the antibodies used 
were anti-TNF-a-fluorescein isothiocyanate (Mab 11 from BD), anti-CD95-phycoerythrin 
(DX2 from BD), anti-IFN-y-phycoerythrin-Cy7 (B27 from BD), anti-CD28-PerCP-Cy5 .5. 
(L293 from BD), anti-IL-2-allophycyanin (MQI-17HI2 from BD), anti-CD4-1J;pC!an 
(L200 from BD), anti-CD3-Alexa fluor 700 (SP34.2 from BD), and ant(-CP8a-ARC-c 
(SKI from BD). 
o 
~ 
~ 
~LU4· T lymphocyte counts and LU4 ·m"hor!§9PstlSJWhole bl collected in 
a 
3 
EDT A was surface stained with an anti-CD4-FITC, anti-CD95- '$: & 
3 
APC, anti-CD28-PE. Pedphenlr blood phocyte counts were calculated by cO o 
~ 
~ Df CDrOD4+vt' lymphocytes by the total lymphocyte counts. Z 
r 
Jl 
lJl
al,n afve, and effector memory cells were calculated by m III 
n 
:::T 
··ages of CD28+CD95+, CD28+CD9Y, and CD28TD95+ T cr r 
ii3 
-< 
o 
::JS'"by the total lymphocyte counts. 
<­
per well of 5 /-1g/ml anti-human gamma interferon (IFN-y) antibody (B27; BD 
Pharmingen) in endotoxin-free Dulbecco's PBS (D-PBS). The plates were then washed 
three times with D-PBS containing 0.25% Tween-20, blocked for 2 h with D-PBS 
containing 5% fetal bovine serum to remove the Tween 20, and incubated with peptide 
pools and 2x105 PBMCs in triplicate in 100-/-11 reaction mixture volumes. The peptide 
pool used in this study spanning the SIVmac239 Gag protein was comprised of 15 amino 
IFN-y ELlSPOT assays. 
III 
::J 
c 
III 
-< 
~ 
.w 
~Multiscreen 96-well plates were coated overnight with 100/-11 o 
<0 
8 

$: 
~ 
3 
o 
.a 
acid peptides overlapping by II amino acids. Each peptide in a pool was present at a 1 
2 fJg/ml concentration. Following an 18 h incubation at 37°C, the plates were washed 9 
3 times with D-PBS containing 0.25% Tween-20 and once with distilled water. The plates 
4 were then incubated with 2 fJg/ml biotinylated rabbit anti-human IFN-y (Biosource) for 2 
5 h at room temperature, washed six times with Coulter Wash (Beckman Coulter) .. and 

6 incubated for 2.5 h with a 1 :500 dilution of streptavidin-alkaline pho~~ 

7 Biotechnology). After five washes with Coulter Wash and ....on6with D-PI\SHt(e plates 

o 
o 
8 were developed with NBTIBCIP chromogen (Pie by ~ 
~ 
~9 washing with tap water, and the plates.p.....Av..,. zyme-linked 
a­
3 
10 immunospot (ELISPOT) reader (ill 
11 processing software (vpl'Jj6n 4.1) (Me 
~ 
, 
~12 z 
:II 
m 
CI)13 RBMC stfin)dation aD!l intracellular cytokine staining. Purified PBMCs were isolated II> 
n 
,
:T 
lated blood and incubated at 37°C in a 5% C02 environment for cr14 ot:Q OJ 
-< 
o 
::Jence of RPMI 1640-10% fetal calf serum alone (unstimulated), a pool of <­15 
II> 
::J 
C 
II>16 -mer Gag peptides (5 fJg/ml [each peptide)), or staphylococcal enterotoxin B (5 fJg/ml; 
-< 
.w 
I\) 
o17 Sigma-Aldrich) as a positive control. All cultures contained monensin (GolgiStop; BD o 
<0 
18 Biosciences) as well as 1 fJg/ml of anti-CD49d (BD Biosciences). The cultured cells 
19 were stained with monoclonal antibodies specific for cell surface molecules (CD3, CD4, 
20 CD8, CD28, and CD95) and with an amine dye (Invitrogen) to discriminate live from 
21 dead cells. After being fixed with CytofixlCytoperrn solution (BD Biosciences), cells 
22 were perrneabilized and stained with antibodies specific for IFN-y, TNF-a, and IL-2. 
23 Labeled cells were fixed in 1.5% formaldehyde-phosphate-buffered saline. Samples were 
9 
o 
o 
~ 
o 
collected on an LSR II instrument (BD Biosceiences) and analyzed using FlowJo 
2 software (Tree Star). Approximately 200,000 to 1,000,000 events were collected per 
3 sample. The background level of cytokine staining varied within different samples and 
4 different cytokine patterns, but was typically <0.01 % of the CD4+ T cells (median, 0%) 
5 and <0.05% of the CD8+ T cells (median, 0.01 %). All data are reported after back~onnd 
6 correction. The only samples considered positive were those in which 
7 cytokine-staining cells was at least twice that of the backgr:owfd. 
8 
~ 
9 Virus neutralization assay. Plasma s~ p.I!" ~ .....ttl'l-rom all '];A..mfected animals ~ 
a 
3 
10 immediately prior to intrarectal ex irus. Neutralizing antibodies s: ill 
'"3 
o11 were measured in a luq. at utilized either TZM-bl or 
.a 
!!!. 
s:12 5.25.EGFR:.Qjc:.! deScribed previously (33). The 50% inhibitory z 
r 
:0 
(!) 
as the."rasma dilution that resulted in a 50% reduction in '" re 
o 
::y 
'units (RLU) compared to virus control wells after subtraction of C' r 
OJ 
-< 
o 
:J
"RLU. Assay stocks of un cloned SIVsmE660 were generated in CEMx174 c... 
:J '" C 
16 Us. Assay stocks of the Env-pseudotyped virus, SIVmac2511CS.4I, was generated by 
-<'" 
~ 
s» 
I\) 
o17 co-transfection of a SIVmac251CS Env plasmid and an Env-deficient HIV backbone o 
<!) 
18 plasmid (pSG3~Env) in 293T cells. Both viral stocks were made cell free by filtration 
19 through 0.45-micrometer pores and stored at -70°C until use. 
20 
21 Statistical analyses. Statistical analyses and graphical presentations were computed with 
22 GraphPad Prism, using nonparametric Wilcoxon rank sum tests and Mann-Whitney U 
23 test. P values of <0.05 were considered significant. 
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Results 
SIVmac251 and SIVsmE660 differ by typical intraclade HIV-l distance. To evaluate 
the genetic relatedness of two isolates of SlY that are frequently used in nonhuman 
primate studies, we compared the genetic distance between SIVmac25I and SIYsrnE660 
to intraclade and interclade HIY-l sequence distances. We used HIV clade B and ~ 
sequences in the Los Alamos HIY Sequence Database to generate our ~tjp:tafes of.J-II\{-l 
interclade and intraclade diversity. We used one sequence.p 
o 
~alignments. We analyzed 11,484 pairs of sequen gag, 21,1' airs 0 ::l 
2" 
a. 
a.for env, 32,465 pairs of sequences for n~'mJU or pol. Figure 1 (l) 
a 
3 
shows the distribution of normalize<J~"{!~cjO: cent similarity of intraclade and ~: ill 
en 
3 
interclade pairwise co tance between SIV srnE660 and cO o 
~ 
~SIVmac2Sn tgag, pol, env and n~l"ijre pl'6tted in each panel. As shown in Figures lA Z 
r 
:IJ 
(l) 
(l)aod B, th~ di~tance btID\een ~arand env of the two SIV strains is similar to HIV -1 clades en III 
n 
:::T 
Band~ int:lite)allediMances, with a distance of 0.91 and 0.83 respectively. In contrast, fr r 
i» 
-< 
o 
::lthe'idf'!fiaItCf)'~between the two SlY isolates inpol and nefare of the magnitude seen in <­
III 
::l 
C 
IIIiJlterclade differences in HIV-1 (Figures 1 C and D). Therefore, these two pathogenic 
-< 
~ 
.w 
aSlY isolates are well-suited strains for use in a SIV model of superinfection because their a 
f\) 
<D 
two key foci, env and gag, have differences that reflect a degree of sequence 
heterogeneity comparable to different circulating HIV -1 isolates within the same clade. 
Plasma SIV RNA levels following primary infection. We then established cohorts of 
rhesus monkeys that were infected with one or the other of these two strains of SlY. The 
viruses and routes of administration used to initiate these infections are summarized in 
11 
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Table 1. Eight animals were initially infected with SIVmac251 (Fig. 2A) and six animals 
were initially infected with SIVsmE660 (Fig. 2B). Infection was successfully established 
in 9 of these 14 monkeys via intrarectal route. However, 5 of 14 monkeys did not exhibit 
detectable viremia after 18 sequential intrarectal inoculations and had to be inoculated 
intravenously to initiate the primary infection (CR53, A V74, CG5G with SIVIQ'lc2 
CR54, CP37 with SIVsmE660). 
Viral replication during primary infection occurred .with Jd 
o 
replication in naIve rhesus monkeys. Moreover, .SW·renlkation ltfn!.tics did't\QJ;:dfffer ~ 
2" 
a. 
~significantly between animals that bec'!IBtfiJltectfl([bYAIlUCbsal or inf!ra'\7enous routes. g 
3 
Monkeys that were infected "Y.ith S~a<;~jn de'{eloped uniform peak plasma viral -s: 
i:>J 
(J) 
3 
RNA levels of6-7Iog(attf4 days afte"xv.i\p~ntiCJlTation followed by a sustained viremia c.O o 
a 
s;:
thewexception of one monkey (CT76) which had Z 
r 
Jl 
CD 
CD 
IlJ700'da-ys post-infection. 
(J) 
o 
:::r 
lP th~co. of monkeys infected by SIV smE660, monkeys had peak plasma r 6' 
iil 
-< 
o 
:J 
'­IlJ 
:J 
C 
i.tiremia of 5-7 logs of plasma viral RNA in animals CP37 and CP23. However, three of 
-< 
IlJ 
~ 
S" 
I\) 
othe monkeys infected with SIVsmE660 (CP3C, CG7G, AK9F) had undetectable plasma o 
co 
viral RNA levels by 700 days post-infection, while monkey CR54 had undetectable 
plasma viral RNA levels by 85 days post-infection. This wide range in peak and set point 
viremias in monkeys infected with SIVsmE660 has been previously described (7,19,35). 
Since plasma viral RNA levels at peak and set point in some of the SlYsmE660-infected 
monkeys (CP37, CP23, CG7G) were of a magnitude comparable to that seen in monkeys 
following SIVmac251 infection, the variability in SIYsmE660 replication levels in 
12 
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monkeys likely reflects a host factor effect rather than an intrinsic lack of replicative 
capacity of the SIVsmE660 strain. 
Plasma SIV RNA levels following superinfection. Once set point plasma virus RNA 
levels were reached, all monkeys were exposed to the heterologous virus by 6 ~feR:Jy 
intrarectal inoculations. The duration of primary infection and plasma 
at time of exposure to the second virus are summarized in T.aOIe.lt'~The 
o 
o 
infected and 6 SIVsmE660-infected monkeys we nitore ~ 
6' 
n. '" 
n.superinfection by assessing plasma SI'£,t 1V~ eekly for 20 (1) g 
3 
5:weeks. ~ 
3 
each SIV strain in the dually-
.a 
oTo monitor the 
~ 
~ infected I1!1 0/$.. we oped ~~T-PeR assay using strain-specific probes. Figure 3 Z 
r 
:D 
ffi 
(1)shows th~ rep licatio eticS"t'tft he two strains of SIV following the first and second 
n'" 
:::T 
0' 
iil
,icleB in Fig. 3A, 6 of 6 monkeys that were initially infected with r 
-< 
became superinfected with SIV mac251. Of the 8 monkeys that were L 
o 
:::J 
:::J '" C 
i,l'IiEially infected with SIVmac251, 6 became superinfected with SIVsmE660 (Fig. 3B). 
-<'" 
.w 
I\) 
oViral RNA of the heterologous SIV strain was detected by 14-21 days after challenge. In o 
<0 
11 of 12 superinfected animals, with the exception of AK9F, the levels of plasma viral 
RNA of the second virus at peak viremia were 1 to 4 logs lower than the peak viremia of 
the first virus. In addition, the levels of plasma viral RNA of the second virus also 
declined rapidly to undetectable levels in 6 animals (CR54, CP23, CR53, PBE, AH4X, 
CG71), while the viral load persisted at low levels in the remaining 6 animals (CP37, 
13 

CG7G, CP3C, AK9F, CPIW, CT76). The presence of the superinfecting virus at 
2 multiple time points was confirmed in each animal by direct sequencing. 
3 Of the 14 infected animals that were exposed to a heterologous virus, only 2 
4 
5 
6 
7 
8 
~9 No apparent acceleration in disease n~s~iBfperinfedtoil . Interestingly, 
a 
3 
~: 
i» 
'" 3 
to " ~ 
s;: 
Z 
r 
JJ 
m 
(1) 
II> () 
3" 
r 
fr Ql 
-< 
o 
:::l 
<­
II> 
:::l 
C 
II> 
-< 
5.J 
I\) 
a17 superinfection and a small increase in the CD4+ T cell counts in some of the animals was a 
<t) 
18 observed from 42 to 126 days after superinfection (CT76, CPIW, CG71, CP3C, AK9F, 
19 CG7G). We did not perform statistical analyses on the differences in the CD4+ T cell 
20 decline between superinfected and nonsuperinfected animals due to the small sample size 
21 of animals that resisted superinfection, but the trend in changes of CD4+ T cell counts 
22 were indistinguishable between all animals. Therefore, there appeared to be no 
(AV74, CG5G) that were initially infected with SIVrnac251 resisted superinfection with 
the heterologous virus (Fig. 3C). There was no detectable SlYsmE660 viral 
these animals for 20 weeks after exposure. The absence of replicati 
virus was verified by direct sequencing (data not shown). 
o 
~ 
~ 
a. 
10 primary virus (Figure 3A and 
11 3B) and a transient aeq~ t\.!2J:l.~"g superinfection in all of the animals, 
12 finding is consistent with case reports of 
13 1111vvlvU individuals developed a transient perturbation 
14 1tltal--pJasm( vifilJitNA levels in association with a clinical prodrome that aroused 
15 IIfCfoiNfi[t an an intervening event might have caused a sudden rise in viral load (2, 
16 27, 42, 60, 67). The CD4+ T cell counts are re-equilibrated 2-6 weeks after 
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acceleration in disease progress in the superinfected monkeys as a consequence of 
superinfection. 
Peak viral replication following the second infection was lower than peak viral 
replication following the first infection. Of the 12 monkeys that became supS!.Q nii 
11 animals efficiently controlled the second virus at peak viremia, witl<{ 
AK9F. Peak replication following the second virus infecti9n~8S(6wer tl\an peak 
CJ 
replication after the first infection in each monke .g. . ThOOle'crease i 1.1 ~ g­
o. 
a 
~viremia was statistically significant as de.Idbilin p;nred WilCo~On rank sum test 
3 
(p= 0.001) . Furthermore, when co '$: i» (j) 
3 
following the second iJiltl ,at.t>bserved following the first infection 
.0 
o 
~ 
);(Fig.5B). ence in the I11edj1an v~lues and interquartile ranges of peak viremia Z 
r 
::IJ 
between tpe'first and(Se'~ono"'iT!f-eftions was statistically significant as determined by the m Sl> <t> 
<3 
::r 
r 
cr 
OJ 
-< 
o 
::l 
'­Sl> 
::l 
C 
S'ttsceptibility to superinfection was not associated with time after the first infection Sl> 
-< 
S.> 
oor persistence of the primary virus. In these 2 cohorts of monkeys, superinfection was o 
I\) 
CD 
initiated between 3 and 20 months after the primary infection (Table 1). This large 
window of susceptibility suggests that infected individuals are likely susceptible to 
superinfection regardless of the state of immune competence of the host or the maturity 
of the immune response to the initial virus. Superinfection can occur after the immune 
response against the initial infection has had time to develop and mature. In addition, 
since 10 of 12 superinfected animals harbored the Mamu-A *01, -B*08, -B* 17 alleles, 
Ilp~M 
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(Table 1), susceptibility to superinfection appears not to be a consequence of major 
histocompatibility complex alleles that are associated with relatively efficient viral 
control. 
Furthermore, the likelihood of acquiring a second virus appears not to be 
th,e first v." 
correlated with the persistence of replication of the primary virus at the time o:(..~xp 
to the heterologous virus (Table 1). Some animals became superinfec 
relatively high levels of replication of the primary virus, ra bm 10\ 106.....RNA 
o 
o 
copies/ml in the plasma (CP23, CP37, CPIW, PB 	 d CR5~)..!Yflfile :;; ::::l 
~ 
~others became superinfected in the setti 	 r low lev'd.-re plication of the g 
3 
primary virus, ranging from 102_103 	 he plasma (CP3C, CG7G, AK9F, "$: ill 
(f) 
3 
oCR54, CT76). <!3 
~ 
~ad cMiigh set point viremia following exposure to 	 Z 
r 
:II 
(1) 
CPIW, CR53, PBE, AH4X, and CG71) or SIVsmE660 (f) (1) I» 
o 
:::T 
'Second virus was efficiently controlled after superinfection while 	 fr r 
ill 
-< 
o 
::::lcting virus remained the predominant viral quasi species in the plasma. In 	 <­
I» 
::::l 
C 
trast, in animals that had undetectable plasma viral RNA levels following expusre to 	
-< 
I» 
.w 
oSIVsmE660 (CG7G, CP3C, and AK9F) or SIVmac251 (CT76) prior to superinfection, 	 o 
r\) 
<0 
the heterologous virus replaced the first viral strain after superinfection even in monkeys 
with blunted peak replication of the second virus. Only one monkey in the cohort, CR54, 
was able to control both viruses to undetectable levels. These data suggest that, although 
direct viral interference did not contribute to susceptibility to superinfection, it may have 
influenced the viral replication dynamics of the second virus relative to the primary virus 
after superinfection. 
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Susceptibility to superinfection was not associated with absolute CD4+ T cell counts 
or percent central memory CD4+ T cells. To determine if there were any clinical 
parameters associated with relative susceptibility to superinfection in these cohorts of 
monkeys, we assessed the absolute CD4+ T cell counts and the percentage of CD4 
lymphocytes that were central memory cells immediately prior to th~ (lX es 
animals to the heterologous virus. There was no difference~ 'D4+ T...c.ell 
o 
a 
counts or the percentage of CD4+ central memory. the ahiitbtls that '1leCaffie ~ 
2' 
0. 
~superinfected and those that resisted su and B). 'Although a 
a 
3 
statistical analysis could not be pel . s observation due to the small s: ~ 
3 
osample size of animals he absolute CD4+ T cell counts and to 
~ 
~the oercent:8sze.<:)t:..celttrMmemorv €D4+ 1"cells of animals that resisted superinfection Z 
r 
:0 
3l ~ere witl1in"the rangerof th2"eerresponding parameters in animals that became Sl 
o 
:::T 
rIIbberlDfecte'd. Iii"":"a.c1diiion, we also analyzed the percentages of effector and nai've 0' 
iil 
-< 
a 
:::l\~v~4+ T cells and found that there were no differences in these values between c... 
~ 
:::l 
C 
~ th~two groups of monkeys (data not shown). Together, these data indicate that animals 
-< 
Y' 
owith immune systems that are more damaged by a prior SlY infection appeared not to o 
f\.) 
<0 
have an increased susceptibility to superinfection. 
Susceptibility to superinfection was not associated with virus-specific cellular 
immune responses. To determine whether systemic virus-specific cellular immune 
responses conferred protection against heterologous virus in the monkeys that resisted 
superinfection, all rhesus monkeys were evaluated for SlY-specific cellular immunity 
17 
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ru 
to the sma).:l~s 
re.sponse" 
immediately prior to exposure to the heterologous virus. Cellular immunity to SIV was 
first evaluated using an Elispot assay to assess PBMC IFNy responses following exposure 
to a pool of SIV Gag peptides (Fig. 7 A). SIV -specific T cell responses were 
indistinguishable between the animals that became superinfected and those that resisted 
superinfection. 
SIV-specific CD4+ and CD8+ T lymphocyte function were furt 
intracellular cytokine staining. Immediately prior to exposu 
PBMC production of IFNy, TNFu, and IL-2 wer~after stim'\llation Wim.s1V 	 ~ g­
o. 
Gag peptide pools. We were able to de '04+ (Fig~B) and CD8+ (Fig. 	 ~ 
a 
3 
7C) T lymphocyte responses in PH . ....We did not perform statistical "5ill : 
tJ) 
3 
analyses on the differe ween the two groups of monkeys due ca o 
e>. 
~
'at resisted superinfection. However, the cytokine 	 z 
r 
JJ 
CD 
tJ) 
CDmais-1tta-("resisted superinfection were within the range of the 	 III 
o 
:T 
r _~ers in animals that became superinfected. Therefore, the 	 6' 
iil 
-< 
o 
:J\ mtalftmi~d quantitative cell-mediated SIV-specific immune responses of monkeys 	
<­
III 
:J 
C 
IIItttrit became superinfected and those that resisted superinfection appeared to be 	
-< 
.w 
~indistinguishable. These findings suggest that SIV -specific cellular immune responses 	 o 
<0 
likely did not account for the variability in the susceptibility of these monkeys to 
superinfection. 
Antibody responses did not protect against superinfection. The role of neutralizing 
antibody responses in protecting against HIV superinfetion is not clear (5,49,50). To 
assess whether SIV-specific antibodies played a role in the resistance to superinfection in 
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these cohorts of animals, plasma samples harvested just prior to the heterologous viral 
challenge were assayed for neutralizing antibody responses elicited by the primary SIV 
infection. The ability of plasma antibody to neutralize SIVsmE660 and SIVmac251 was 
measured in luciferase reporter gene neutralizing antibody assays using uncloned 
SIVsmE660 and pseudoviruses expressing viral Envelope cloned from SIVmac251 
(33). The serum IDso neutralizing titers against both viruses are showIrih:Fanle 2 
Plasma from 5 of 6 monkeys (except CR54) that were first in with SJV~660 
o 
neutralized the homologous SIVsmE660 (1:62 to ..lf..50S1:::w.hile plasma from'fi o.J.8' ~ 
0' 
~ Q. 
a 
~SIVmac251-infected monkeys neutrali~@d1tPmo1..o~~mac251 t'i;33 to 1:215). 
3 
To investigate whether the ?lilti~,o9i4pner~by these animals following ~: i» 
C/) 
3 
primary infection have~abilily to n~li~~fteterologous virus, we assayed the <0 o 
~ 
plasma of..ti'fe.mooIrevs\fut .peutrallia.tion 'a'Ctivity against the second virus before their ~ 
r 
:IJ 
(1) 
e.xposure lJ,o ipat virur.'"'"'~s S'hown in Table 2, animals initially infected with SIVsmE660 C/) re 
o 
:::y 
rlienerat&.d uh<ietecrabll or low titer neutralizing antibodies to SIVmac251 (ranging from cr 
~ 
-< 
o \~t~tlle"to 1 :41) .. We also detected neutralizing antibodies against SIVsmE660 in 6 :::J 
'-­~ 
:::J 
C 
~ animals that were initially infected with SIVmac251 (ranging from 1:73 to 1:245). ~ 
-< 
~ 
I\) 
oHowever, the titers against the heterologous SIVsmE660 in the SIVmac251-infected o 
co 
animals were not significantly lower than the titers againsted the homologous 
SIVsmE660 in SIVsmE660-infected animals (p=0.95, Mann-Whitney test). 
Interestingly, animals A V74 and CG5G, which were initially infected with 
SIVmac251 and subsequently resisted superinfection with SIVsmE660, had neutralizing 
antibodies against SIVsmE660 prior to exposure to this heterologous virus. However, the 
titers of these antibodies were within the range of antibody titers against SIVsmE660 that 
19 
were generated by other SlY mac251-infected animals that became superinfected 
2 following exposure to SIYsmE660. We did not perform statistical analyses of the 
3 differences in antibody titers against SIVsmE660 between the SIVmac251-infected 
4 monkeys that resisted superinfection and the SlY mac251-infected monkeys that became 
12 
5 superinfected because of the small number of animals that resisted superinfection. 

6 Nevertheless, the titers of neutralizing antibodies specific for the het~r~ogoUs vi 

7 that were elicited during primary infection appears to not hav! 

o 
o 
8 susceptibility of monkeys to superinfection. 
lI;•."PP~ 
~ 
6" go 
c. 
a 
~9 
10 Discussion 3 
11 HlY superinfection has imp~ or vaccine prevention of HlY -s: fll 
3 
11 this study, we used intrarectal (:) U3 
~ 
s;:13 inoculations of ....tw.o:reolieition-comoeteni"Strains of SlY to simulate HlY-1 Z 
r 
:IJ 
(1) 
14 ~4perinfe'¢o.n and erpt)\oyeH-ttua"ntitative analyses of viral RNA using strain-specific C/I(1) go 
o 
:::T 
15 D'rl~o dldi n2tfie.replication dynamics of each virus over time. We demonstrated that 6' r 
iil 
-< 
o 
:::>16 UllHiUfie restronses generated dming primary infection that are capable of controlling one c.... go 
:::> 
c 
17 s-train of SlY do not preclude subsequent infection with a second strain of SlY. go 
-< 
.c" 
~18 Superinfection occurred as early as 3 months and as late as 2 years following primary o 
<D 
19 infection and susceptibilities to superinfection appeared to be independent of classical 
20 adaptive immune responses or the level of replication of the primary virus, even though 
21 we were not able to evaluate the statistical significance of these parameters because of the 
22 small number of animals that resisted superinfection in this study. Importantly, the 
23 replication of the superinfecting virus during the first days following exposure was 
24 attenuated compared with the replication of the primary virus. The relative susceptibility 
20 
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e 
of monkeys to superinfection in the present study could not be attributed to a difference 
in the replication capacities of these two strains of SIV, since superinfection occurred in 
both cohorts of animals regardless of which virus was used to establish the first infection. 
Furthermore, the ability of both SIVmac251 and SIVsmE660 to maintain dominance in 
superinfected monkeys suggests that these two SIV strains are comparable in their 
fitness . 
Previous nonhuman primate studies using a live att~nG~ 
o 
virus to generate protection against a pathogenic jm1hgp~ficien' ~ 
~ 
a 
~provide an important context for the J u'~lIY"ugh suchJwe attenuated pr.s<~
3 
viruses can confer protection again s challenge (11 , 14, 25, 36, 57 , 	 '5: ill 
en 
3 
64), they provide only terologous virus infection (16, 34, 	
.a 
o 
~ 
~dy are consistent with those findings in that prior 	 Z 
r 
Jl 
CDinfection 'Pi, n:t superinfection with a heterologous virus, but did damp 	 3l 
n'" 
:::T 
crnd virus at peak and in the post-acute phase of superinfection. 	 r 
iil 
-< 
o liltm'e~timtJ~ the 2 animals that resisted superinfection had also resisted 18 attempts at L'" 
'" 
'" 
the-first infection by the intrarectal route and required intravenous inoculation to establish 	
-<'" 
c 
_w 
oprimary infection. This finding raises the possibility that variations in the mucosal barrier 	 o 
f\) 
<D 
rather than specific immunological mechanisms may have contributed to differences in 
susceptibility to mucosal infection in this cohort of animals (29). 
Just as the correlates of protective immunity have not yet been defined for the 
protection observed in monkeys that have received a live attenuated SIV vaccine (1, 3, 
11, 44, 45, 54, 55), the mechanisms accounting for the partial protection observed against 
superinfection are not clear. We used pooled peptides corresponding to SIVmac239 Gag 
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W 
to evaluate virus-specific cellular immune responses because the cross-reactive responses 
are likely the most germane to controlling the replication of the heterologous virus. 
Nevertheless, there may be additional T cell responses that contribute to controlling the 
second virus that are not detected using SIVmac239 peptides. It is possible that the total 
cell-mediated response to both viruses contributed to the relative control of each. virus ton 
superinfected animals . A recent study by Reynolds et ai. examining t 
attenuated SIV to protect macaques against heterologous v!J;utchap-enge1 
o 
o 
MHC class I-restricted CD8+ cellular responses i heterM020us vir 	 ~ 
0' 
III 
C. 
a 
~during the chronic phase of infection (4 	 r studies needed to 
3 
elucidate the relative contributions '0 .other factors , including CD4+ T 	 -s: ill 
VI 
3 
cells, antibodies, and if replication of the second virus. A 	
.a" 
~ 
~ get~cells as a result of depletion of memory CD4+ 	 Z 
r 
:D 
(1) 
pri~ttre gut and lymph nodes following the first infection may VI re 
n 
::r 
o tne reduction and magnitude of peak viremia observed following the 0' r 
ii3 
-< 
o 
:::>recond' inmtfion. Further detailed characterization of CCR5+ transitional and effector 	
<­
III 
:::> 
c 
IIIftte"'mory T cells in mucosal effector sites are needed to determine the availability of target 	
-< 
_w 
ocells . Other factors , such as innate immune responses or viral interference, may have 	 o 
I\) 
<0 
also contributed to the relative protection observed against the superinfecting virus. 
The present study of superinfection in the SIV/rhesus monkey model has 
important implications for HIV pathogenesis and vaccine development. Although this 
SIV model of superinfection utilized a higher dose mucosal challenge to establish 
superinfection than likely occurs in human cases of HIV superinfection, the findings in 
the present study suggest that HIV superinfection can occur readily throughout the course 
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of infection. Therefore, the prevalence of HIV superinfection is likely underestimated, 
especially in cases whose only clinical manifestation is transient low-level replication of 
the second virus. Interestingly, similar to human cases of HIV superinfection described 
by Casado and Piantadosi, et at (8, 40), SIV superinfection in the present study also did 
have clini 
not necessarily lead to increases in viral load and clinical deterioration. This could~ 
because both SIV strains that were used in this study are comparably fi erefore t, 
persistence of either one or both may not dramatically affeq..dUea$f In 
o 
o 
contrast, the clinical sequelae in HIV superinfectioJ.t1riivbave m ~ 
2 
a. 
~than what we have observed in this stu9YfSiPce ~~.1dynamic\»f the two viruses (f 
3 
may be markedly different as a coIl' tive replication fitness . ~: ill 
C/) 
3 
Although superinfecti ~nn1l1enon in HIV-1 infections, it may not 	
.a 
o 
~ 
);:
viru'Ses are equivalent in their fitness or if the 	 Z 
r 
JJ 
C1l 
C1l 
!l> 'eplicates at a low level. In contrast to this, 	
C/) 
o 
:::T 
r 
.M.s a profound impact on the sensitivity of circulating viruses to 	 6' 
iil 
-< 
o ' antU\ffio~rtherapy and global HIV genetic diversity as a consequence of viral 	 :::> 
'-­!l> 
:::> 
c 
!l> 
recombination. 	
-< 
.w 
I\) 
aCreating a vaccine that can protect against infection by a virus with the genetic 	 a 
CD 
heterogeneity of HIV is a daunting challenge, given that immune responses generated 
after live SIV infection do not prevent infection of macaques by a heterologous SIV 
isolate in the nonhuman primate model. Nevertheless, the phenomenon of HIV/SIV 
superinfection should not discourage the pursuit of an AIDS vaccine, since effective 
vaccines for viruses such as mumps and measles do not prevent entry of virus into the 
body. While the immune system does not prevent new strains of virus from establishing 
23 

work 
o 
o 
:;; 
::J 
1 infections, it can limit the spread of those viruses and attenuate the pathogenic sequelae 
2 of infection. Further dissection of the virologic and immune correlates of protection 
3 against superinfection in monkeys may provide important insights into the nature of 
4 immune responses that are required to provide protective immunity against an 
5 immunodeficiency virus infection. 
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Figure Legends 
Figure 1. Genetic distances between SIVrnac251 and SIVsrnE660 in relation to 
HIV-1 clade Band C intraclade and interclade distances. We performed pairwise 
comparisons of 11,484 gag (A), 21,177 env (B), 7140 poL (C), and 32,465 nef(D) 
sequences from indi viduals infected with HIV -1. The genetic distance for each,of tb 
comparisons was graphed as fractional simjlarity between a given pair fX-¢ s). 
amplitude of the bar graph reflects the percentage of pairwi"~' 
given sirilliarity (Y-axis). Comparisons betweeny w 
and pairs of sequences from different cl :S.ll'ed by shalliKg: intraclade B 
o 
o 
~ 
6' 
III 
a. 
~ 
a 
3 
(light hatched bars), intraclad~ C ( B versus C (dark hatched bars). s: ill 
'"3 
Genetic distances betw sroE660 sequences were simjlarly cO o 
~ 
~ calculatedAiiI<Lolotte"d simu ltaneotiSlV at e'ach genetic locus as black diamonds . 	 z 
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:0 
CD 
CD 
III '" 
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rF~l!m+2. Plu.oiii'V.iJal RNA levels following primary infection with either SIVmac251 	 6' 
iil 
-< 
o 
:::J60. (A) Six rhesus monkeys were infected with SIVmac251, and (B) eight 	
<­
III 
:::J 
c: 
re infected with SIVsmE660 via either intrarectal (IR) or intravenous (IV) 	
-< 
III 
.w 
~inoculations. Although the animals were infected after different numbers of intrarectal 	 o 
~ 
exposures or a single intravenous inoculation, the viral RNA levels are displayed 
synchronously as days post-infection. Viral RNA levels are shown as log10 copies of 
plasma viral RNA/ml of plasma for individual monkeys at each time point. 
Figure 3. Plasma viral RNA levels of both SIV strains following the primary infection 
and superinfection in each individual monkey. Monkeys were either first infected with 
32 

symbols represent RNA levels of SIVsmE660, while the blue lines and symbols represent 
14 
15 
1 SIVsmE660 and then with SIVmac251 (A), or first with SIVmac25I followed by 
2 SIVsmE660 (B ). Only two monkeys that were initially infected with SIVmac251 resisted 
3 superinfection with SIVsmE660 after 6 intrarectal challenges (C). The red lines and 
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5 plasma RNA levels of SIVmac251. 
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7 Figure 4. Absolute CD4+ T cell counts for 126 days after SJl 
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Whitney U test (p<O.OOO 1) was used to evaluate the statistical significance of the 
2 differences between the peak viremias at the two time points. 
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4 Figure 6. Resistance to SIV superinfection was not associated with peripheral blood 
11 animals that resisted s 
12 
5 absolute CD4+ counts or central memory CD4+ T cells at the time 
he 
of exposure J.q thl~ 

6 superinfecting virus. (A) CD4+ T lymphocyte counts on the day of ch~ge 

7 heterologous SIV isolate did not differ between the monkey. 

o 
o 
8 and those that resisted superinfection. 
,_~ryCD4+ 
(B) There 	 nt differeneein ~ 
0" 
III 
Q. 
~9 these groups of monkeys in the percent 	 lvmphocytes as 
(3 
3 
10 identified by their expression of C dashed boxes highlight the 	 '$: i» 
(fJ 
3 
o 
.a 
~ 
);: 
Z 
r 
JJ 
C1lsup'et'i-ntection was not associated with SIV Gag-specific CD4+ 	 III 
m13 Eigure 7. 
(i 
~ 
r14 atH1~CD8+ 'Nympn~yte responses at the time of exposure to the superinfecting virus. 	 6' 
~ 
-< 
o 
:J15 ,treraLbfood lymphocytes obtained from the monkeys prior to challenge with the 	
<­
III 
:J 
C 
III16 su15'erinfecting virus were exposed to a pool of overlapping SIV Gag peptides and their 	
-< 
S..> 
I\) 
o17 responses were assessed in IFN-y ELISPOT assays (A) and intracellular cytokine staining 	 o 
co 
18 assays. Gating on CD4 + (B) or CD8+ (C) T lymphocytes, the cells were assessed for 
19 production of TNF-a, lFN-y, and lL-2. The dashed boxes highlight the animals that 
20 resisted superinfection. 
21 
34 

•(J) <: 
0 
iD 
;:::::;::::::::::::::::::: '" 
:.:-: .:-:.;.:-:-: :.:-:.;.:.;.:.:.; .:-:.:-: .:-:-:-:.:-:.;. 
.....::.:.:.: ..... :.:.:.;.:.:.;. 
Frequency, normalized Frequency, normalized 

a a ;:;, 0 '" ~ u; 0 '" 0 
'" ~ ~ to>'" '" '" I0 '" l>a 0.77 t------t 
(Jo 
'" 0.78 
a 

m 
 0.79 '" 
a 
.... 
'" 0.81 ' 
a 
CD 0.82 ,"Ed'" 
a 0.83 
CD 
'" 0.84 
a 

Co 
 0.85 
0.86 
.. 
a 
~ 
() a 
, 'lil(-, CQ1 g [088 
: 

'(J)

• 
'" 
'"[
;;; 
Co ~'I' iD "" 
a ~ ~ 0.89 :<OJ ~ Co 
• 
,!=>(-, 
,
CD
­'" --iiZ f: 0.9 ,IJ a 
CoOJ .,. ~ .......... ... .... .... . 

cD 
0 
Co 
(Jo 
a 

Co 
 (' 0.94 m 
a I O.~ 
Co 
.... 
a 

Co 
 ""---- O:W , 
CD , 
a 1l,g8 ' )Co 
CD (Q"
_. 
0.99 4t 
c: 
-t 
Frequency, normalized fl'l.queiW:-(l°rmalized 
a .,. a ;;; A a; c;:; C m CDCD to> to>a ~ ~ 0 '" 
0.68 I I I '" '" 0.68 
.....L 
0.690,7 
0.7 
0.71, 
, 0.72
'u> 
0.74 , ' 'e: 0.73 
'P"'l!, 
,'O! 0.74 
0.76 . . : , 
0.75 
0.760 ,78 g;;r=4 • 
0.77 
.......... ....... . 
0.78 0.8 
, 
,• \!! ' OJ 0.82 (-, '" CJ) 08 < , I 
'" 

....... 1 

t1>

(-, [l ~. P , !~ .. 
 g: ,EJ 'I' of 0813' 
iii' 0.84 -
::, 
'" ~
'"cD ,., le:6Jo'4Jse'!II[ WOJj papeOIUMOO
............ ......... 
 600 2 ~~~
.:c "­II 
... .... .... .. () 0.86(-, 
0.88 
0.9 
0.92 
0 .89 
0.9 0.94 
0.91 
0.92 0 .96 
0.93 
0.98 0.94 
Fi
gu
re
 2
 
A
 
s ,...
 
O
l 
.
2
- E
 
u;
 
Q
) 00.
 
o
 
o
 
« z
 
a:
 
C'IS
 E III C'IS it
 
o
 
::
J <
­
III
 
::
J c:
 
-
< III 
.
.
.
 
CP
3C
 (I
R)
 
-
<>
-
CG
7G
 (I 
R) 
-
e
-
AK
9F
 (I
R)
 
~ Q) 
.
.
.
 
CP
23
 (I
R)
 
0a. 
.
.
.
.
.
 
CR
54
 (I
V)
 
8 
.
.
.
.
.
 
C
P3
7 
(IV
) 
«
 
z a:
 
C'IS
 E III C'IS it
 
10
 
10
0 
10
00
 
D
ay
s 
Po
st
-In
fe
ct
io
n 
0 0 ::;: :::l
Fi
gu
re
 3
 
III
 
0"
 
-
< 
CG
7G
 
0 
E 
8 
:::
l 
-
'-
­
III
 
-
< :::l 
•
C
U
) 
Cl
) 
III
 
SI
Vs
m
E6
60
.
-
6 
6 
_
w
Co
 
0 
I\
) 
0 
SI
Vm
ac
25
1 
(J
 
0 
•
CD
 
«
 
Z a:
 
20
0 
40
0 
60
0 
80
0 
20
0 
40
0 
60
0 
80
0 
co
 E U) 
-
C
P3
C
co
 
8 
8 
a..
 
6 
6 
4 
4 
2 
2 


20
0 
40
0 
60
0 
80
0 
20
0 
40
0 
60
0 
80
0 


D
ay
s 
Po
st
-In
fe
ct
io
n 
C
. 
A 
co
 
c
.
-
8 
C
P3
7 
8 
C
R
54
 
6 
6 
4 
-0 ,..
. 
2 
C
) 
50
 
,
­
0 
fr
-
iil
-
"
 
4 
2 
2 
A
K
9F
 
•
 •
 
0 0 ::; ~
Fi
gu
re
 3
 	
III
 0"
 
C
. 
CD
 
B
 	
a c. 
8 6 4 
-0 ,...
. 
2 
C
) 


0

- - E
 
U
) 
- (1
)
.
­ C
. 
0 0 «
 
z a:
 
cu
 E U) 
-
cu
 
8 
c..
 
6 4 2 
3 s:
C
P1
W
 
s;: ill
8 
U
l 3 a cO
 
6 
~ z r JJ CD Ul CD III ;:; :::T
20
0 
40
0 
60
0 
20
0 
40
0 
60
0 
80
0 
	
r 0'
 
Ii! 
-
< 0 ~
A
H
4X
 
c..
.. 
4 2 
	
gj 
SI
Vs
m
E6
60
 
c III
 
.
:::>
 
6 
	
~
 
SI
Vm
ac
25
1 
.
w
 
I\J
 
a a <D
 
20
0 
40
0 
60
0 
80
0 
	
10
0 
20
0 
30
0 
40
0 
50
0 
CG
71
 	
CT
7G
8 6 4 2 
50
 
10
0 
15
0 
20
0 
25
0 
20
0 
40
0 
60
0 
80
0 
D
ay
s 
Po
st
-I 
n
fe
ct
io
n 
0 0 ::E ~
Fi
gu
re
 3
 
2" Cl. CD Cl. 
-0 T"
" 
C
) 
0 :::
.. 
8 
E -UJ .~
 
6 
Q
. 
0 (J
 
«
 
4 
Z a:
 
m
 
2
E 
50
 
10
0 
15
0 
20
0 
25
0
UJ
 
~ s: ill en 3 
C 
a 0 a
 
CG
5G
 
A
V7
4 
6 4 
.
w
 
'"
 
2 
jg
 
a.
 
D
ay
s 
Po
st
-In
fe
ct
io
n 
•
 
SI
Vs
m
E6
60
 
•
 
SI
Vm
ac
25
1 

•
•
 
A 


-0 ,..
..
 
C
) 
.
2 - E
 
U
) 
-


Q)
.
0..
 
6 
0 (.)
 
5 
«
 
Z 
4 
[t:
 
co
 
3
E U) co 
2 
D.
 
0 :E :::J
Fi
gu
re
 5
 
0 0"
 
a
. 
'"
 
CD
 
a
. ~ ~: g, '" 3 
B 
a (:) ca ~ Z r CD
P:
0.
00
1 
:JJ
 
P<
0.
00
01
 
CD
 
'"
 
'"<l
C
) 
:T
 
r rr
 
-
-
-
< iil 0 
-
:::
J 
'
­
u; 
:1:
-
'"
 
'"
 
:::
J 
•
•
Q)
 
c
. 
0 
_
Vl
(.)
 
f\
) 
«
 
0 0
-
-
< c: 
:1·­
<
0
Z a:
 
co
 E U) co 
2 
pr
im
ar
y 
in
fe
ct
io
n 
su
pe
rin
fe
ct
io
n 
il:
 
pr
im
ar
y 
in
fe
ct
io
n 
su
pe
rin
fe
ct
io
n 
CD4+ T cells/JlI » 
CP3C 
CP37 
CG7G 
AK9F 
CP23 
CR54 
CP1W 
CT76 
PBE 
CR53 
CG71 
AH4X1--------­
: AV74 
I 
..... ..... ..... ..... 
I: CG5G I _________ • ______________________ : __~------~ 
CP3C 
CP37 
CG7G 
AK9F 
CP23 
CR54 
CP1W 
CT76 
PBE 
CR53 
CG71 
AH4X 
,- --- --- -­
: AV74 
I 
: CG5G 
1 ______ --­
0/0 CM CD4+ T cells 
."
-.(Q 
c: 
~ 
CD 
en 
SFC/106 PBMC l> 11
-. (Q
CP3C CCP37 ..., 
CG7G CD 
AK9F 
-..J CP23 
CR54 
CP1W 

CT76 

PBE 

CR53 

CG71 

% C08+ Cytokine+ T cells 04+ Cytokine+ T cells OJ 
0 o o o 

b i-l :.:.. c" 
 :.:.. c" 

CP3C 

CP37 I~D 
:;; -I 
Z Z 
CG7G 
+ --< "T1 
+ RAK9F + 
CP23 
CR54 
CP1W 
CT76 
PBE 
CR53 
CG71 
, 
, , 
,i~~~~:E__________________: , , 
, 
~ 
________________, 
CP3C 
CP37 
CG7G 
AK9F 
CP23 
CG71 
~ 
I\) :.:.. c" en b i-l 
o o o 
j= 
~ 
o NeJQ!l 4:lJeasal::llN'v'lle 6Jo"WSe"!A! WOJI papeolUMoa 
-----------------------------------~ 
o 
en 0 i-l :.:.. 
Ta
bl
e 
1.
 V
iru
se
s,
 r
o
u
te
s 
of
 in
fe
ct
io
n,
 v
ira
l l
oa
d,
 a
nd
 ti
m
e 
of
 s
u
pe
rin
fe
ct
io
n 
M
on
ke
 
M
H
C
-c
la
ss
 I·
 
c
tio
n 
CP
3C
 
A
*0
1,
8*
17
 
Ye
s :0 
CG
7G
 
SI
Vs
m
E6
60
 
A*
01
,8
*1
7 
77
5 
Y~
 
AK
9F
 
Sf
Vs
m
E6
60
 
8*
17
 
fR
 
74
8 
Y~
 
CP
23
 
Sf
Vs
m
E6
60
 
A*
01
 
fR
 
l6
8 
SI
Vm
ac
25
1 
Y
£ 
CR
54
 
Sf
Vs
m
E6
60
 
A*
01
 
IV
 
1'1
)5 
SI
Vm
ac
25
1 
Y
a 
CP
37
 
SI
Vs
m
E6
60
 
A*
01
 
IV
 
10
5 
Sf
Vm
ac
25
1 
Y~
 
0 ::>
 
CP
1W
 
Sf
Vm
ac
25
1 
A
*0
1,
8*
08
 
m
 
6.
98
x1
04
 
Sl
Vs
m
E6
60
 
Y~
 
CT
76
 
Sl
Vm
ac
25
1 
A*
01
 
77
5 
2.
45
x1
02
 
Sl
Vs
m
E6
60
 
Y
i 
PB
E 
Sl
Vm
ac
25
1 
74
8 
4.
85
x1
05
 
Sl
Vs
m
E6
60
 
Y
~
 
CG
71
 
Sl
Vm
ac
25
1 
A 
7 
10
5 
1.
12
x1
05
 
SI
Vs
m
E6
60
 
Y~
 
AH
4X
 
SI
Vm
ac
25
1 
36
5 
6.
23
x1
04
 
Sf
Vs
m
E6
60
 
Y~
.
.
 
. .
 
.
 
_
_
 
-
_
.
 
K
.
.
~
.
 
_
:
.
' 
_
'
,
 
-
.
 
-
.
 
-
: 
.
 
::'''
~:--
-
-
.
.
.
.
 
=
-
-
-
~
~
:
.
~
 
'
: 
a 
M
H
C-
cla
ss
 I 
a
lle
le
s 
ty
pe
d 
w
e
re
 M
am
u-
A 
*
01
,
 
-
A
*
02
, 
-
8*
08
, a
nd
 -8
*1
7.
 A
lle
le
s 
th
at
 a
re
 p
re
se
nt
 
in 
e
a
ch
 m
o
n
e
y 
a
re
 in
di
ca
te
d.
 N
eg
 in
di
ca
te
s 
al
l f
ou
r a
lle
le
s 
w
e
re
 n
o
t d
et
ec
te
d.
 
b 
R
ou
te
 o
f p
rim
ar
y 
in
fe
ct
io
n:
 IR
, i
nt
ra
re
ct
al
 in
fe
ct
io
n;
 IV
, i
nt
ra
ve
no
us
 in
fe
ct
io
n 
C 
Se
t p
oi
nt
 p
la
sm
a 
vir
al
 R
N
A 
in 
co
pi
es
/m
l o
f p
rim
ar
y 
vi
ru
s 
a
t t
im
e 
of
 e
xp
os
ur
e 
to
 s
e
co
n
d 
vi
ru
s 
d 
Al
l m
o
n
ke
ys
 w
e
re
 e
xp
os
ed
 to
 th
e 
se
co
n
d 
vi
ru
s 
via
 in
tra
re
ct
al
 in
oc
ul
at
io
n 
e 
M
on
ke
ys
 th
at
 re
si
st
ed
 s
u
pe
rin
fe
ct
io
n 
a
re
 h
ig
hl
ig
ht
ed
 in
 g
ra
y.
 
Ta
bl
e 
2.
 
N
eu
tra
liz
in
g 
a
n
tib
od
ie
s 
in 
rh
es
us
 a
n
im
al
s 
a
fte
r p
rim
ar
y 
in
fe
ct
io
n 
pr
io
r t
 
10
50
 in
 T
ZM
-b
l c
e
lls
a 
A
ni
m
al
 
Pr
im
ar
y 
Vi
ru
s 
Oa
~s
 
SI
Vm
ac
25
1/
CS
.4
1°
 
CP
3C
 
SI
Vs
m
E6
60
 
76
8 
<
20
 
:IJ
 
(1)
 
(1)
 
III
 
CG
7G
 
SI
Vs
m
E6
60
 
77
5 
<
20
 	
(J)
 C'l
A
K
9F
 
SI
Vs
m
E6
60
 
74
8 
	
:T
 
CP
23
 
SI
Vs
m
E6
60
 
76
8 
	
r- C
' til
CR
54
 
SI
Vs
m
E6
60
 
10
5 
	
<
20
 
-
< 
CP
37
 
SI
Vs
m
E6
60
 
10
5 
79
 
0 ::J
 
<
­
III
 
::
J c 
CP
1W
 
43
 
24
5 
	
III
 
-
< ~
CT
76
 
SI
Vm
ac
2 
50
 
11
0 
S"
 
PB
E 
SI
Vm
ac
25
 
50
 
<
20
 
0 0 I\
) 
CG
71
 
SI
Vm
ac
25
 
<
20
 
18
8 
<
D 
A
H
4X
 
SI
Vm
ac
25
1 
33
 
12
0 
CR
53
 
SI
Vm
ac
25
1 
21
5 
<
20
 
.
 
~
~
.
 -
:-
-
:. 
' 
-
.
: 
<:
 ~.
-	
-
-
-
: 
:
:
:
 
-~
_~
__
::
 
: 
:_-
~ 
~ -.,
.
: 
~ 
~'
T 
_
~ 
_
 
_
 
=
 
_
_
_
 
_
 
,.~'
..
w
 
.
.
.
.
.
 
	
_
 
a 
Va
lu
es
 a
re
 th
e 
sa
m
pl
e 
se
ru
m
 d
ilu
tio
n 
at
 w
hi
ch
 r
e
la
tiv
e 
lu
m
in
es
ce
nc
e 
u
n
its
 (R
LU
) w
e
re
 r
e
du
ce
d 


50
%
 c
o
m
pa
re
d 
to
 v
iru
s 
co
n
tro
l w
e
lls
 (n
o s
e
ru
m
 s
a
m
pl
e).
 

b 
Ps
eu
do
vi
ru
s 
co
n
ta
in
in
g 
En
v 
cl
on
ed
 fr
om
 s
in
gl
e 
e
xp
an
sio
n 
of
 u
n
cl
on
ed
 S
IV
m
ac
25
1 
ch
al
le
ng
e 


st
oc
k 
w
e
re
 g
en
er
at
ed
 in
 2
93
T 
ce
lls
. 

c 
Un
clo
ne
d 
SI
Vs
m
E6
60
 v
iru
s 
st
oc
k 
w
e
re
 g
en
er
at
ed
 in
 C
EM
x1
74
 c
el
ls.
 

dM
on
ke
ys
 th
at
 r
e
si
st
ed
 s
u
pe
rin
fe
ct
io
n 
ar
e 
hi
gh
lig
ht
ed
 in
 g
ra
y.
 

